(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual revenue growth rate of 34.91% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Dianthus Therapeutics's revenue in 2025 is $6,524,000.On average, 6 Wall Street analysts forecast DNTH's revenue for 2025 to be $141,825,521, with the lowest DNTH revenue forecast at $37,305,579, and the highest DNTH revenue forecast at $218,366,278. On average, 4 Wall Street analysts forecast DNTH's revenue for 2026 to be $183,151,097, with the lowest DNTH revenue forecast at $149,543,916, and the highest DNTH revenue forecast at $229,300,672.
In 2027, DNTH is forecast to generate $577,432,477 in revenue, with the lowest revenue forecast at $192,959,892 and the highest revenue forecast at $1,682,931,858.